Home  »  Finance   »  Kiniksa Pharmaceuticals Ltd. (KNSA) Offers An Exce...

Kiniksa Pharmaceuticals Ltd. (KNSA) Offers An Excellent Investment Opportunity At Current Levels

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) concluded the trading at $15.60 on Wednesday, November 23 with a fall of -1.64% from its closing price on previous day.

Taking a look at stock we notice that its last check on previous day was $15.86 and 5Y monthly beta was reading -0.23 with its price kept floating in the range of $15.54 and $16.78 on the day. Company’s P/E ratio for the trailing 12 months is 7.81. Considering stock’s 52-week price range provides that KNSA hit a high price of $16.67 and saw its price falling to a low level of $7.36 during that period. Over a period of past 1-month, stock came adding 29.03% in its value.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


With its current market valuation of $1.06 billion, Kiniksa Pharmaceuticals Ltd. is set to declare its quarterly results on Feb 20, 2023 – Feb 24, 2023. Analysts are in estimates of $0.5 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to -$0.43 for 2022 with estimates of that growing to -$0.95 in next year. These estimates are suggesting current year growth of 81.30% for EPS and -120.90% growth next year.

Analysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $74.39 million. They suggested that in the process company could generate revenue of as low as $33.73 million which could climb up to $114.96 million to hit a high. The average estimate is representing an increase of 630.70% in sales growth from that of posted by the company in the same quarter of last year. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $173.98 million in 2022, which will be 351.40% more from revenue generated by the company last year.

In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In contrast, when we review KNSA stock’s current outlook then short term indicators are assigning it an average of 100% Buy, while medium term indicators are categorizing the stock at an average of 100% Buy. Long term indicators are suggesting an average of 100% Buy for it.

Digging deeper we become aware of the PEG ratio of the KNSA stock which is currently positioned at 0. It further provides that stock’s current price level is 9.51% away from its 20-day simple moving average and is 18.73% off its SMA50. Its relative strength index (RSI) for 14-periods is oscillating at 63.23 while volatility remained at 5.95% over the past week which changes to 6.69% when measuring it over the past month. Beta is valued at -0.25, while measure of average true range or ATR is currently at 0.90.

In comparing Kiniksa Pharmaceuticals Ltd. (KNSA)’s stock with other industry players reveals that stock’s current price change of -1.64% and that of 32.20% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price raised by 0.11% in the last trading and went through an increase of 10.16% in past 12-month trading. Industry’s another major player Eli Lilly and Company (LLY) has rise 0.23% up in previous session, but over the past year has faced a rise of 38.08%, while AbbVie Inc. (ABBV) was also down -0.25% however its price remained floating in the green at 34.08% over the same period. Kiniksa Pharmaceuticals Ltd. has a P/E ratio of 7.81 against that of Johnson & Johnson’s 24.64 while Eli Lilly and Company is showing 54.36 for the same. On the other hand, the S&P 500 Index was up 0.59% in the last trading session while the Dow Jones Industrial closed the session higher at 0.28%.

Having a second look at Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) provides that stock’s average daily trading volume for 3 months was 342.34K, while it jumped to 0.34 million when we calculate an average volume for past 10 days. Number of outstanding shares of the stock stood at 69.44 million.

The percentage of outstanding shares held by the insiders is 0.30% while it is 45.30% for the institutional holders. The figures also indicate that as of Oct 13, 2022, number of stock’s short shares was 2.65 million which implies a short ratio of 7.25. This shows up a 3.82% of Short Interest in company’s outstanding shares on the day. In October the standing of shares short improved as it was 2.43 million in the previous month. Addition of 32.54% by stock’s current price to its year-to-date value in last trading session is likely to be increasing investors’ interest in the stock as it is hinting an extended uptrend.

Leave a Comment

Your email address will not be published. Required fields are marked *